1.Liang W，et al.Impact of examined lymph node count on precise staging and long-term survival of resected nonsmall-cell lung cancer：a population study of the US SEER database and a Chinese Multi-Institutional Registry.J Clin Oncol，2016，JCO2016675140.

2.Song J，et al.Non-small cell lung cancer：quantitative phenotypic analysis of CT images as a potential marker of prognosis.Sci Rep，2016，6；6：38282.

3.Chen KZ，et al.Circulating tumor DNA detection in early-stage non-small cell lung cancer patients by targeted sequencing.Sci Rep，2016，6：31985.

4.Tong JH，et al.MET amplification and exon 14 splice site mutation define unique molecular subgroups of nonsmall cell lung carcinoma with poor prognosis.Clin Cancer Res，2016，22：3048-3056.

5.Liu SY，et al.The unique characteristics of MET exon 14 mutation in Chinese patients with NSCLC.J Thorac Oncol，2016，11：1503-1510.

6.Li F，et al.Identification of TRA2B-DNAH5 fusion as a novel oncogenic driver in human lung squamous cell carcinoma.Cell Res，2016，26：1149-1164.

7.Mok T，et al.Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC patients treated with first-line Intercalated erlotinib and chemotherapy.Clin Cancer Res，2015，21：3196-3203.

8.Zhou Q，et al.Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trial.J Hematol Oncol，2016，9：86.

9.Cheng Y，et al.Randomized phase Ⅱ trial of gefitinib with and without pemetrexed as first-line therapy in patients with advanced nonsquamous non-small-cell lung cancer with activating epidermal growth factor receptor mutations.J Clin Oncol，2016，34：3258-3266.

10.Mok TS，et al.Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer.N Engl J Med，2017，376：629-640.

11.Li YS，et al.Leptomeningeal metastases in patients with NSCLC with EGFR mutations.J Thorac Oncol，2016，11：1962-1969.

12.Jiang T，et al.EGFR TKIs plus WBRT demonstrated no survival benefit other than that of TKIs alone in patients with NSCLC and EGFR mutation and brain metastases.J Thorac Oncol，2016，11：1718-1728.

13.Yang Z，et al.AZD3759，a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases.Sci Transl Med，2016，8：368ra172.

14.Yang JC，et al.Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma（LUX-Lung 3 and LUX-Lung 6）：analysis of overall survival data from two randomised，phase 3 trials.Lancet Oncol，2015.16：141-151.

15.Yang JC，et al.Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma：post hoc analyses of the randomized LUX-Lung 3 and 6 trials.Ann Oncol，2016，27：2103-2110.

16.Brahmer J，et al.Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer.N Engl J Med，2015，373：123-135.

17.Borghaei H，et al.Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer.N Engl J Med，2015，373：1627-1639.

18.Herbst RS，et al.Pembrolizumab versus docetaxel for previously treated，PD-L1-positive，advanced non-smallcell lung cancer（KEYNOTE-010）：a randomised controlled trial.Lancet，2016，387：1540-1550.

19.Fehrenbacher L，et al.Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer（POPLAR）：a multicentre，open-label，phase 2 randomised controlled trial.Lancet，2016，387：1837-1846.

20.Hong S，et al.Upregulation of PD-L1 by EML4-ALK fusion protein mediates the immune escape in ALK positive NSCLC：Implication for optional anti-PD-1/PD-L1 immune therapy for ALK-TKIs sensitive and resistant NSCLC patients.Oncoimmunology，2015，5：e1094598.eCollection 2016.

21.Bezjak A，et al.Intensity-modulated radiotherapy in the treatment of lung cancer.Clin Oncol（R Coll Radiol），2012，24：508-520.

22.Chen AB，et al.Comparative effectiveness of intensity-modulated versus 3D conformal radiation therapy among medicare patients with stage Ⅲ lung cancer.J Thorac Oncol，2014，9：1788-1795.

23.Harris JP，et al.A population-based comparative effectiveness study of radiation therapy techniques in stage Ⅲnon-small cell lung cancer.Int J Radiat Oncol Biol Phys，2014，88：872-884.

24.Liao ZX，et al.Influence of technologic advances on outcomes in patients with unresectable，locally advanced non-small-cell lung cancer receiving concomitant chemoradiotherapy.Int J Radiat Oncol Biol Phys，2010，76：775-781.

25.Ling DC，et al.Comparison of toxicity between intensity-modulated radiotherapy and 3-Dimensional conformal radiotherapy for locally advanced non-small-cell lung cancer.Clin Lung Cancer，2016，17：18-23.

26.Wang J，et al.Intensity-modulated radiation therapy may improve local-regional tumor control for locally advanced non-small cell lung cancer compared with three-dimensional conformal radiation therapy.Oncologist，2016，21：1530-1537.

27.Zhao Q，et al.Phase Ⅲ study of cisplatin with pemtrexed or vinorelbine plus concurrent late course accelerated hyperfractionated radiotherapy in patients with unresectable stage Ⅲ non-small cell lung cancer.Oncotarget，2016，7：8422-8431.

28.Yu H，et al.The clinical effects of low-dose splenic irradiation combined with chest three-dimensional conformal radiotherapy on patients with locally advanced non-small-cell lung cancer：a randomized clinical trial.Onco Targets Ther，2016，9：5545-5552.